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Molecular Systems Biology of ErbB1 Signaling: Bridging the Gap through
Multiscale Modeling and High-Performance Computing
Abstract
The complexity in intracellular signaling mechanisms relevant for the conquest of many diseases resides
at different levels of organization with scales ranging from the subatomic realm relevant to catalytic
functions of enzymes to the mesoscopic realm relevant to the cooperative association of molecular
assemblies and membrane processes. Consequently, the challenge of representing and quantifying
functional or dysfunctional modules within the networks remains due to the current limitations in our
understanding of mesoscopic biology, i.e., how the components assemble into functional molecular
ensembles. A multiscale approach is necessary to treat a hierarchy of interactions ranging from
molecular (nm, ns) to signaling (μm, ms) length and time scales, which necessitates the development and
application of specialized modeling tools. Complementary to multiscale experimentation (encompassing
structural biology, mechanistic enzymology, cell biology, and single molecule studies) multiscale
modeling offers a powerful and quantitative alternative for the study of functional intracellular signaling
modules. Here, we describe the application of a multiscale approach to signaling mediated by the ErbB1
receptor which constitutes a network hub for the cell’s proliferative, migratory, and survival programs.
Through our multiscale model, we mechanistically describe how point-mutations in the ErbB1 receptor
can profoundly alter signaling characteristics leading to the onset of oncogenic transformations.
Specifically, we describe how the point mutations induce cascading fragility mechanisms at the molecular
scale as well as at the scale of the signaling network to preferentially activate the survival factor Akt. We
provide a quantitative explanation for how the hallmark of preferential Akt activation in cell-lines
harboring the constitutively active mutant ErbB1 receptors causes these cell-lines to be addicted to
ErbB1-mediated generation of survival signals. Consequently, inhibition of ErbB1 activity leads to a
remarkable therapeutic response in the addicted cell lines.
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The complexity in intracellular signaling mechanisms relevant for the conquest of many diseases resides at
different levels of organization with scales ranging from the subatomic realm relevant to catalytic functions of
enzymes to the mesoscopic realm relevant to the cooperative association of molecular assemblies and membrane
processes. Consequently, the challenge of representing and quantifying functional or dysfunctional modules
within the networks remains due to the current limitations in our understanding of mesoscopic biology, i.e., how
the components assemble into functional molecular ensembles. A multiscale approach is necessary to treat a
hierarchy of interactions ranging from molecular (nm, ns) to signaling (mm, ms) length and time scales, which
necessitates the development and application of specialized modeling tools. Complementary to multiscale
experimentation (encompassing structural biology, mechanistic enzymology, cell biology, and single molecule
studies) multiscale modeling offers a powerful and quantitative alternative for the study of functional intracellular
signaling modules. Here, we describe the application of a multiscale approach to signaling mediated by the
ErbB1 receptor which constitutes a network hub for the cell’s proliferative, migratory, and survival programs.
Through our multiscale model, we mechanistically describe how point-mutations in the ErbB1 receptor can
profoundly alter signaling characteristics leading to the onset of oncogenic transformations. Specifically, we
describe how the point mutations induce cascading fragility mechanisms at the molecular scale as well as at the
scale of the signaling network to preferentially activate the survival factor Akt. We provide a quantitative
explanation for how the hallmark of preferential Akt activation in cell-lines harboring the constitutively active
mutant ErbB1 receptors causes these cell-lines to be addicted to ErbB1-mediated generation of survival signals.
Consequently, inhibition of ErbB1 activity leads to a remarkable therapeutic response in the addicted cell lines.
a
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Skirkanich Hall, Philadelphia, PA 19104,
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b
Genomics and Computational Biology
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c
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Introduction
ErbB family receptors (named because of
their homology to the erythroblastoma
viral gene product, v-erbB, and consisting
of the epidermal growth factor receptor
or EGFR/ErbB1/HER1, ErbB2/HER2,
ErbB3, and ErbB4) signal by activating
crucial pathways1 in response to activation by ligands such as the epidermal

Andrew J. Shih (top) is a ﬁfth year PhD candidate in
the Department of Bioengineering at the University of
Pennsylvania. He works on understanding the structural biology of ErbB receptor kinases through computational simulation techniques. Jeremy Purvis is a fourth
year PhD student in the Genomics and Computational
Biology Graduate Group at the University of Pennsylvania. He is currently working on understanding the
behavior of growth factor signaling networks as they
relate to cancer and developing a signaling model of the
human platelet using a combination of high-throughput
experiments and computational modeling.
Andrew J. Shih (top) and
Jeremy Purvis (bottom)
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growth factor (EGF) and other related
peptide growth factors. Through ligandstimulated formation of various homodimeric and heterodimeric complexes, ErbB
receptors are activated, leading to the
phosphorylation of multiple tyrosine
residues on the C-terminal tail of the
receptors as well as on other substrate
proteins. Through speciﬁc interactions of
the phospho-tyrosine sites to binding
domains, the receptors bind to cytosolic
partners that are responsible for the recruitment and activation of multiple
down-stream cascades.2–7 Activation
through the mitogen-activated protein
kinase (MAPK) cascades of the extracellular signal-regulated kinases (ERKs) is
functionally linked to proliferation. The
phosphoinositide 3-kinase (PI3K) pathway leads to the activation of the serine/
threonine protein kinase Akt (cellular
homologue of the viral oncogene v-Akt)
which is linked to survival. Other signiﬁcant pathways mediated by ErbB
signaling include activation and nuclear
translocation of signal transducers and
activators of transcription proteins
Mol. BioSyst., 2008, 4, 1151–1159 | 1151
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(STATs)8 and clathrin mediated endocytosis.9 Yet, the molecular context in
which ErbB receptors activate and regulate signaling has not been fully recognized. More speciﬁcally, it is of great
interest to investigate the molecular mechanisms that lead to the disregulation of
ErbB signaling in several pathologies
such as cancer, psoriasis, atherosclerosis,
impaired cardiac development, and schizophrenia.10,11 With rapid progress in
high-performance computing methods
and infrastructure,w we advocate that
multiscale modeling oﬀers a powerful,
quantitative, and complimentary alternative for the study of functional intracellular
modules. We describe the application
of a hierarchical multiscale modeling
procedure (summarized in the section:
Models and methods) to signaling in
ErbB family receptors to describe how
point-mutations in the ErbB1 receptor
can profoundly alter signaling characteristics leading to the onset of oncogenic
transformations.

the dimer-mediated receptor activation
characteristics of the ErbB1 receptor tyrosine kinase using molecular dynamics
simulations.12,13 Fig. 1a depicts the atomistic model of the explicitly solvated
ErbB1 kinase dimer employed in the
molecular dynamics: 10–30 ns trajectories
of fully atomistic, explicitly solvated systems of wildtype and mutant ErbB1
kinase monomers and dimers are obtained
and analyzed for speciﬁc stabilizing interactions such as hydrogen bonds and
salt-bridges, see also Fig. 2.12,13 Based on
the model in Fig. 1a, we also model the
interactions of ErbB1 substrate tyrosines
derived from the C-terminal tail of ErbB1
with the kinase using molecular docking
simulations.12 Speciﬁcally, we perform a
global conformational search for bound
conformations of substrate peptides to the
ErbB1 kinase domain using a multiple
conformation docking strategy in which
the protein ﬂexibility is taken into account
implicitly. We treat receptor-mediated signaling using a deterministic networkbased kinetic model,12,14,15 see Fig. 1b:
the ﬁgure depicts the branched signaling
network model for ErbB1-mediated
signaling employed in this study. In the
branched kinetic model, signaling through
ErbB1 is modeled by combining three
published models and augmented by
our own set of reactions: phosphorylation
and docking reactions are modeled
according to ref. 5; the MAPK pathway
reactions are modeled after ref. 3; Akt and
PI3K activation are incorporated into the
model as described in ref. 16. We resolve
phosphorylation of the active ErbB1
dimer at tyrosine site Y1068, which
when phosphorylated can bind to growthfactor-receptor bound-2 protein (Grb2)
or Grb2-associated binding protein

(GAB-1), or at tyrosine site Y1173, which
when phosphorylated can bind to the
Src-homology-2-containing (Shc) adaptor
protein. Phosphorylation of downstream
factors Akt and ERK are used as indicators of downstream activation (see also
Table 1). Diﬀerences in ERK and Akt
phosphorylation levels due to mutations
in the ErbB1 receptor are accounted for
through changes to the kinetic parameters
of the deterministic model. The altered
parameters are obtained through a
combination of our molecular dynamics
and molecular docking simulations as well
as through experiments published in the
literature.15 Altogether, our network
model comprises 74 reactions and 67
species. 17 of these reactions are novel
to this work and represent enhanced
molecular resolution in the ErbB1 activation, phosphorylation, and docking
reactions, and enable separate parameterization for ErbB1 wildtype and mutant
systems.12,14,15 Recently, we have extended the signaling module to include
ErbB1 receptor internalization, which we
treat using a hybrid discrete/continuum
stochastic
dynamics
protocol.12,17,18
Fig. 1c depicts the hybrid stochastic model
for ErbB1 internalization: (top) grids in
ﬁnite diﬀerence scheme for solving membrane dynamics (based on a continuum
ﬁeld model) and for modeling protein
diﬀusion via lattice hopping; (bottom)
snapshot of vesicle bud on the membrane
in response to a speciﬁc spatial ordering of
the curvature-inducing protein, epsin, on
the membrane.

Ravi Radhakrishnan (Assistant Professor of Bioengineering) obtained his PhD in chemical physics from the
Department of Chemical Engineering at Cornell University in 2001. After two postdoctoral assignments in
chemical physics and biophysics at MIT and at the New
York University/Howard Hughes Medical Institute, he
joined the faculty of the University of Pennsylvania in
2004. He has a background in chemical physics and
molecular biophysics, and is involved in developing
multiscale modeling and simulation protocols to predict
single molecule properties as well as signal transduction
mechanisms for mammalian systems.

Small molecule tyrosine kinase inhibitors
for ErbB1/2 tyrosine kinase such as geﬁtinib, erlotinib, and lapatinib, which are
ATP analogues, are of signiﬁcant interest
as cancer drugs. While the receptor tyrosine kinase inhibition approach has
shown promise in some clinical trials,
success has been mixed. In particular,
the occurrence of somatic mutations in
the ErbB1 kinase domain (L834R: where
the leucine residue in position 834 is
replaced by an arginine, L837Q: leucine
at 837 replaced by a glutamine, G685S,
del L723–P729 ins S: deletion of residues

Models and methods
We provide a brief summary of the hierarchical multiscale modeling scheme we
have employed for describing ErbB signaling (see Fig. 1a–d). The ﬂow of information between the models (summarized
below) is depicted in Fig. 1d. We model
w Our applications of multiscale algorithms to
ErbB signaling are enabled by highperformance computing infrastructure. As we transition from teraﬂops or 1014 ﬂops (ﬂops:
ﬂoating point operations per second) computing to petaﬂops (1015 ﬂops) computing in the
near future, we expect that extension of our
molecular and systems modeling to complete
cellular pathways will become tractable.

Ravi Radhakrishnan
1152 | Mol. BioSyst., 2008, 4, 1151–1159

Rationalizing and predicting
the effects of molecular
perturbations on receptor
kinase activation
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Fig. 1 Hierarchical multiscale modeling scheme for ErbB signaling. The dimer-mediated receptor activation characteristics of ErbB1 receptor
tyrosine kinase are studied using molecular dynamics simulations. The interactions of substrate tyrosine containing peptides derived from the
C-terminal tail with the ErbB1 kinase are studied using molecular docking simulations. We have employed a deterministic network-based kinetic
modeling scheme to study ErbB1-mediated signaling, and a hybrid discrete/continuum stochastic dynamics protocol to study the initiation of
ErbB1 receptor internalization. (a) Atomistic model for ErbB1 dimer employed in the molecular dynamics and molecular docking calculations. (b)
Branched network model for ErbB1-mediated signaling in which phosphorylation of the ErbB1 dimer occurs at either tyrosine Y1068, which can
bind GAB-1 or Grb2, or at tyrosine Y1173, which binds Shc. Phosphorylation of the factors Akt and ERK was used as indication of downstream
activation. (c) Hybrid stochastic model for ErbB1 internalization. (top) Grids in ﬁnite diﬀerence scheme for membrane dynamics and the lattice in
the kinetic Monte Carlo scheme for protein diﬀusion; (bottom) snapshot of vesicle bud on the membrane in response to a speciﬁc spatial ordering
of the curvature-inducing protein, epsin, on the membrane; inset depicts a stabilized vesicle neck. (d) Flow of information between diﬀerent
simulation methods.

723–729 and an insertion of a serine) as
seen in patients of non-small cell lung
cancer19z renders the cell lines harboring such mutations more sensitive to
treatment.19,20
In order to determine how such molecular perturbations can shape cellular
fates, we sought to determine how the
mutations aﬀect the regulatory mechanisms operational within the kinase domain of ErbB1, ErBb2, and ErbB4. A
recent structural and biochemical study
involving ErbB1 by Zhang et al.21 proposed a new dimer-mediated allosteric
activation mechanism according to which
ErbB1 receptor tyrosine kinase dimerizes
in an asymmetric head-to-tail conﬁguration. While the monomer ErbB1 kinase is
stable in an inactive conformation which
interferes with ATP binding, in the asymmetric dimer conﬁguration (see section:
Models and methods), one ErbB1 kinase
z There are 2 main types of lung cancer and
they are treated diﬀerently: small cell lung
cancer and non-small cell lung cancer. About
85% to 90% of all lung cancers are of the nonsmall cell type with three sub-types. The cells
in these sub-types diﬀer in size, shape, and
chemical make-up: (1) squamous cell carcinoma linked to smoking, (2) adenocarcinoma
usually found in the outer part of the lung, and
(3) large-cell (undiﬀerentiated) carcinoma
exhibiting rapid growth and spreading.

This journal is
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domain serves as an activating protein
and activates the other ErbB1 kinase in
the dimer, through allosteric contacts.
The kinase–kinase contact at the asymmetric dimer interface allosterically stabilizes the active conformation. Recently,
we hypothesized that an underlying network of stabilizing hydrogen bonds dominates the relative stabilities of the inactive
and active conformations and governs the
kinase activation. We then performed a
hydrogen bond analysis of the molecular
dynamics data, focusing on the interactions surrounding the activation-loop and
the aC-helix sub-domains in the active
and inactive conformations, and identiﬁed this network, see Fig. 2a and b. The
total number of 27 residues participating
in the stabilizing network in the active
state (residues 1–27 marked in Fig. 2a)
out-numbers the 13 residues participating
in the stabilizing network of the inactive
state (residues 28–40 marked in Fig. 2b).
This stark contrast of 27 to 13 stabilizing
interactions led us to hypothesize that a
particular stimulus such as the asymmetric dimerization is poised to preferentially destabilize the inactive kinase
conformation triggering the conformational change to the active state.
In order to consider the eﬀect of
ErbB1 kinase dimerization on the

The Royal Society of Chemistry 2008

network of stabilizing interactions, we
identiﬁed the protein residues participating in stabilizing bonds that are also
proximal (r3 Å between heavy atoms)
to the residues involved in the formation
of the asymmetric dimer interface,
(which are P675, L679, L680, I682,
V736, L758, V762 in the kinase undergoing activation). The rationale for the
proximity analysis is that the interactions
in the stabilizing network could be compromised due to the molecular level reorganization upon kinase dimerization.
The proximity analysis suggests that 3
out 13 stabilizing residues in the inactive
state may be perturbed or lost upon
dimerization (these are marked with D
in Fig. 2c), which suggests a potential
molecular relay mechanism by which the
kinase dimerization event activates the
kinase domain. Indeed, when we performed 20 ns molecular dynamics simulations of an ErbB1 kinase dimer system
(shown in Fig. 1a), we observed a signiﬁcant rearrangement (change in the
root-mean-squared deviation or RMSD
of 3 Å) of the aC-helix position: see
Fig. 2d, the inset to Fig. 2d shows the
shifting of the aC-helix (top) in the wildtype dimer but no signiﬁcant rearrangement of the activation loop (bottom).
The shift in the aC-helix position was
Mol. BioSyst., 2008, 4, 1151–1159 | 1153
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Fig. 2 (a, b) Stabilizing network residues in ErbB1 kinase in its active and inactive conformations. The numbers in (a, b) correspond to the entries
in (c). Compared to inactive, the active state presents a signiﬁcantly increased number of stabilizing residues, with approximately the same number
of residues aﬀected by the asymmetric dimerization (marked D and boxed red) and mutation (marked M and boxed green); so the inactive system
is much more susceptible to a conformational shift triggered by the asymmetric dimer or mutation. We identify the residues participating in
stabilizing bonds that are also proximal (r3 Å between heavy atoms) to the dimer interface. Cross-referencing this list with the stabilizing residues
provides a list of potential residues possibly aﬀected by dimerization: entries marked D in (c) and boxed red in (a, b). (d): Symbols represent trace
during dimer molecular dynamics simulations of wildtype and the two mutants L834R and Del L723–P729 ins S or del: (top) root-mean-squared
deviation or RMSD of aC-helix, and (bottom) RMSD of the activation loop (or A-loop). Insets depict the relative positions of the aC-helix and the
A-loop at the end of the dynamics runs. The purple corresponds to the inactive conformation, the orange corresponds to the active conformation,
and the green corresponds to the conformation in the wildtype dimer following 20 ns of molecular dynamics from the inactive state. The
conformation of the activation loop stays close to that in the inactive conformation even upon dimerization (see bottom inset). However, the
conformation of the aC-helix in the wildtype dimer undergoes considerable rearrangement and shift toward the active conformation (see top inset).

accompanied by several changes in the
stabilizing network consistent with the
predicted bond-patterns in Fig. 2a–c. In
particular, in the inactive conformation,
the
bonds
between
Y740–S744,
H846–R865, K851–R812 surrounding
the activation loop and the aC-helix were
severed. Thus, already in the wildtype
dimer, due to the re-conﬁguration of
the aC-helix, the bond pattern is found
to be shifting signiﬁcantly toward that
observed in the active kinase. The key
bonds stabilizing the wildtype inactive
ErbB1 kinase are the E738–K836 and
E848–R865 salt bridge interactions, as
well as the L834–D813 hydrogen bond.
In
our
dimer
simulations,
the
E738–K836 salt bridge has considerably
weakened: the fraction of the time this
bond was present decreased from 490%
in the monomer trajectory to B60% in
the dimer trajectory; moreover this bond
has undergone considerable stretching
allowing E738 to hydrogen bond to
F832, which is one of the bonds seen in
the active kinase. The L834–D813 interaction is at the threshold of still being
considered a stabilizing hydrogen bond.
The residue K851 is hydrogen bonded to
E725, moving away from the inactive
bond K851–R812 and towards the active
1154 | Mol. BioSyst., 2008, 4, 1151–1159

salt bridge K851–E734. The E848–R865
salt bridge is not perturbed signiﬁcantly
due to the formation of the asymmetric
dimer interface. Thus, we hypothesize
that a few speciﬁc bonds act as gatekeepers for each step of the conformational change, namely the E738–K836
salt guards against the aC-helix movement and the E848–R865 salt bridge
guards against the activation loop rearrangement. Our dimer simulations reaﬃrm our notion that the stabilizing
network is susceptible to perturbation
in the inactive conformation of the
kinase, and that formation of the asymmetric dimer will have the eﬀect of
directly breaking the network of interactions around the aC-helix, thereby destabilizing the inactive state. The loss of
these interactions and the shift of the
aC-helix conformation towards the
active state will provide the impetus for
kinase domain activation. Intriguingly,
several of the clinically identiﬁed mutations that have been reported to constitutively activate the kinase also directly
perturb the stabilizing network by breaking key stabilizing bonds: these are
marked by the symbol M in Fig. 2c. In
addition, the deletion of residues L723 to
P729 in the del L723–P729 ins S mutant

re-conﬁgures the aC-helix in the inactive
state to a conformation closer to the
active state (data not shown). Thus, our
delineation of the stabilizing hydrogen
bond network provides molecular-level
insight into the possible mechanisms by
which activating mutations of ErbB1
kinase such as L834R and del
L723–P729 ins S destabilize the inactive
conformation. This preferential destabilization of the inactive conformation
renders the receptor kinase constitutively
active even as a monomer, producing
high basal activation levels of the kinase
even in the absence of a growth-factor
induced dimerization.
Considering that there is an excellent
correlation between the stabilizing network of interactions and the clinically
identiﬁed activating mutations in ErbB1,
our structural studies on kinase activation
are well poised to forecast the mutation
landscape associated with other ErbB
members. We have extended the analysis
we have presented for ErbB1 to ErbB2
and ErbB4 kinases in which we have
identiﬁed similar networks of stabilizing
interactions. Based on the similarities between the stabilizing interactions between
ErbB1 and ErbB4 kinase domains, we can
predict the eﬀect of analogous mutations
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Table 1 (a) Comparison of signaling and inhibition characteristics predicted by our network
simulations for wildtype and mutant systems under diﬀerent conditions; Del stands for the
deletion mutant del L723–P729 ins S. Concentrations of Akt-(p) or ERK-(p) are used to indicate
the downstream eﬀects of receptor signaling. EC50 values are calculated as a measure of
the degree to which signals downstream are inhibited by the ATP analogue, erlotinib. (b) Kinetic
rate constants or species concentrations constituting the top three principal components for
network hyper-sensitivity calculated through global sensitivity analysis: kf, turnover for
phosphorylation; () denotes bound complex; the square brackets represent concentrations
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(a)

Wildtype

L834R

Del

ERK-(p) in nM for normal ErbB1 expression
EGF/+EGF
0.2/5.0
1.0/1.0
8.0/8.0
Akt-(p) in nM for normal ErbB1 expression
EGF/+EGF
1.0/15.0
13.0/13.0
20.0/20.0
ERK-(p) in nM for ErbB1 over-expression
EGF/+EGF
3.0/3.0
5.0/5.0
1.0/1.0
Akt-(p) in nM for ErbB1 over-expression
EGF/+EGF
20.0/20.0
22.0/22.0
19.0/19.0
Cellular EC50 in nM for inhibition of ERK-(p) and Akt-(p) for normal ErbB1 expression/ErbB1
over-expression
ERK-(p)
700/4000
100/1000
/
Akt-(p)
1200/500 000
300/50 000
/
(b) Rate and binding constants
kf: Y1068; kf: Y1173
Ki: inhibitor; KM: ATPRTK
KM: GAB-1ErbB1-(p)
Initial concentrations
[RafRasGTP]
[Pase3] phosphatase for ERK-(p)
[Pase4] phosphatase for Akt-(p)
[MEK-(p)]
[PI3K inactive]
[MEKRaf active]
[ErbB1ShcGrb2SOSRasGTP]
[inhibitor]

in ErbB4 on kinase activation: (1) based
on the location of the mutations E690G,
G700S, the mutants are expected to be
activating through directly impacting dimerization (similar to the activating mutants E685G and G695S of ErbB1). (2)
Del 728–G733 ins S and S749I are poised
to cause a conformation shift of the aChelix of ErbB4 and hence are predicted to
be activating. (3) Mutations F740A,
L839R and L842Q in ErbB4 are poised
to perturb the bond network of the inactive kinase and hence are expected to be
activating. We note that in support of our
predictions of ErbB4, the F740A and
L839R have been tested independently by
Qiu et al.22 and were indeed found to be
activating. Based on the subtle diﬀerences
we have noted in the stabilizing bond networks of ErbB1 and ErbB4, we are also
able to suggest new activating ErbB4 mutations (that do not have an obvious
counter-part in the ErbB1 system). In
particular, R841 in ErbB4 is featured prominently in the stabilizing network and
mutating R841 to either alanine or aspartic
This journal is
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acid is expected to promote activation.
Mutation of the two residues blocking
the catalytic aspartate, E743 and G838,
to residues with smaller side chains, alanine or glycine, is also expected to promote
activation. Thus, with experimental validation of the above predictions, we believe
that our approach can be valuable for
evaluating the likely eﬀect of mutations
on ErbB2 inhibition eﬃcacies in cancer,
and ErbB4 inhibition in cardiac development and schizophrenia.11

Differential ErbB1 signaling
due to substrate specificity
and a branched signaling
model for transcribing the
effects of molecular
alterations into downstream
signal activation
The preferential binding characteristics
of diﬀerent cytosolic substrates to diﬀerent phospho-tyrosine locations of ErbB
family kinases were reported recently.23
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The variations in the phosphorylation
kinetics associated with the diﬀerent tyrosine sites of the cytoplasmic C-terminal
tail of the ErbB1 kinase can induce differential patterns of downstream signaling leading to diﬀerences in the
activation of key transcription factors.
This leads us to hypothesize that the
clinically identiﬁed activating mutations
of ErbB1 kinase can also potentially
inﬂuence cellular homeostasis by directly
altering the phosphorylation kinetics
of ErbB1 substrate tyrosines. Indeed
the identity-speciﬁc phospho-tyrosine
kinetics for Y1068 and Y1173 (as well
as other phosphotyrosine sites in ErbB1)
for wildtype, L834R and del L723–P729
ins S mutant systems are supported by
the kinetic experiments of Mulloy et al.24
In particular, the relative catalytic turnover (l = kcat/KM, where kcat represents
the rate of tyrosine phosphorylation in
the bound complex, and KM represents
the aﬃnity of the tyrosine substrate to
the ErbB1 kinase) rates of Y1068 phosphorylation and Y1173 phosphorylation
measured in the experiments are
as follows. For Y1068, wildtype:
log10[lwildtype/l]
=
0.0;
L834R:
log10[lwildtype/l] = 0.0; del L723–P729
ins S: log10[lwildtype/l] = 1.5. For
Y1173, wildtype: log10[lwildtype/l] = 0.0;
L834R: log10[lwildtype/l] = 1.0; del
L723–P729 ins S: log10[lwildtype/l] =
+0.5. The structural basis for the context-speciﬁc kinetics of the C-terminal
tyrosine substrates is provided by our
computational docking calculations:12
substrate peptides derived from tyrosine
sites of the ErbB1 C-terminal tail—
Y1068
(VPEYINQ)
and
Y1173
(NAEYLRV)—bound to the wildtype
and the L834R mutant ErbB1 kinase
revealed how the structure of the bound
peptide–protein complex is altered at the
catalytic site due to the arginine substitution of leucine in L834R.
In order to translate diﬀerences in
substrate speciﬁcity into tangible diﬀerences in the downstream response (ERK
and Akt activation), we introduced a
branched signaling model for ErbB1,
see Fig. 1b, that features two parallel
phosphorylation pathways corresponding to Y1068 and Y1173.12,24 Based on
the results of ref. 23 we developed a
molecularly resolved systems model in
which phosphorylated Y1068 binds only
to Gab-1 and Grb2 and not Shc, and
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phosphorylated Y1173 binds only to Shc
and not to Gab-1 and Grb2 as depicted
in Fig. 1b. We were then able to reparameterize the model based on the
identity-speciﬁc phospho-tyrosine kinetics of Y1068 and Y1173 for wildtype
and mutant (L834R and del L723–P729
ins S) ErbB1 based on the relative catalytic turnover (l) rates.12,24 We were also
able to extend this model for ErbB1
kinase inhibition upon treatment with
small molecule inhibitor erlotinib in
wildtype and mutant, again based on
experimentally available inhibitor/ATP
aﬃnity data.20
Using the diﬀerent parameter values
corresponding to wildtype, L834R, and
del L723–P729 ins S mutant systems, we
ran network simulations for diﬀerent
levels of EGF stimulation and ErbB1
expression levels. The parameters explored were: normal receptor expression
(initial concentration of ErbB1 [ErbB1]
= 100 nM or 30 000 receptors per cell),
and over-expression of ErbB1 (initial
[ErbB1] = 1000 nM or 300 000 receptors
per cell), no EGF stimulation, and 8 nM
(50 ng ml1) EGF stimulation. Based on
the altered l (KM and kcat values derived
form Mulloy et al.24), the L834R had a
stronger preference for both Y1068 and
Y1173 phosphorylation compared to the
wildtype receptor, while the del
L723–P729 ins S mutant showed
increased Y1068 and decreased Y1173
phosphorylation. To gauge the downstream eﬀects of diﬀerential signaling
through Y1068 and Y1173 phosphorylation sites of ErbB1, we calculated the
levels of ERK-(p) (phosphorylated
ERK) and Akt-(p) (phosphorylated
Akt) in our system simulations in response to changes in the phosphortyrosine kinetics (l values) of Y1068 and
Y1173. Table 1a summarizes our simulation results where each entry corresponds
to the peak level of phosphorylation over
a simulated time of 900 s. The eﬀect of
altered aﬃnities of the Y1068 and Y1173
sites to the catalytic domain of ErbB1 is
that the L834R under normal ErbB1
expression exhibits diﬀerential downstream response, i.e., a pronounced decrease in ERK activation (B5-fold) and
relatively smaller decrease Akt activation
(B15% decrease). The del L723–P729
ins S mutant, however, shows sustained
ERK as well as Akt activation relative to
wildtype. For ErbB1 over-expressed
1156 | Mol. BioSyst., 2008, 4, 1151–1159

cells, both ERK and Akt activation characteristics show relative insensitivity to
ErbB1 as a result of signal saturation.
The trends in Table 1a also show that the
mutants can continue to signal even in
the absence of the growth factor. In
addition, the mutant signaling can be
diﬀerent due to changes in the ATP
aﬃnity. However, neither of these factors
introduce any diﬀerential characteristics
(in terms of preferring Y1068 to Y1173);
i.e., each factor impacts the overall activation levels of ERK and Akt uniformly.
Our calculated responses agree with the
qualitative experimental observations of
Sordella et al.19 and Tracy et al.,25 i.e.,
the preferential activation of Akt in
L834R and del L723–P729 ins S mutant
cell lines predicted from our simulations
is consistent with the reported experiments.19,24–26
We also examined the sensitivity of
downstream signaling molecules ERK(p) and Akt-(p) to inhibition by a range
of erlotinib (ErbB1 inhibitor) concentrations. Speciﬁcally, we compute the EC50,
which is the inhibitor concentration at
which 50% of the phosphorylation activity is suppressed in the cellular context,
see Table 1a. Under normal expression
levels of ErbB1, we predict nearly a
7-fold decrease in EC50 for ERK-(p) inhibition for L834R (EC50 = 100 nM)
compared to wildtype (EC50 = 700 nM)
with and without EGF ligand present
(and a 4-fold decrease for over-expressed
ErbB1). With respect to Akt activation,
we report a 4-fold decrease in EC50 for
L834R compared to wildtype (300 nM
vs. 1200 nM) with and without ligand
present15 (and 10-fold decrease for overexpressed ErbB1). These results are
consistent with several experimental results that have reported the eﬀect of the
closely related inhibitor geﬁtinib on normal and non-small cell lung cancer
cells,19,24–26 providing a mechanistic basis for the inhibitor eﬃcacy in mutant cell
lines. This agreement supports the notion
that the branched signaling in our model
can indeed represent a possible mechanism for preferential down-stream activation. In summary, we ﬁnd that the
mutant cell line L834R is more susceptible to inhibition through curbing
downstream (ERK and Akt) activation.
Considering that the absolute Akt-(p)
levels are 5-fold higher than those for
ERK-(p) in the wildtype and 20-fold

higher in the mutant, see Table 1a, the
gain in eﬃcacy with respect to Akt inhibition may be a crucial diﬀerence between the wildtype and the mutant cell
lines. We discuss this aspect below.

Clinical implications from the
multiscale modeling of ErbB
receptor signaling
One of the conditions for cellular
homeostasis can be viewed as a balance
between pro-survival signals and deathinducing signals, both being triggered
and balanced by a variety of interacting
intracellular pathways. Recently, using a
simpliﬁed model for the eﬀect of Akt
activation on cell response,y we showed
that preferential Akt activation is conducive for the cell to rely on (be ‘‘addicted to’’27,28) the most eﬃcient Akt-(p)
generating pathway for generation of
pro-survival signals while requiring the
generation of death-inducing signals
from other pathways. Our simpliﬁed
model illustrates a mechanism by which
inhibiting the dominant source of the
pro-survival signals shifts the cellular
homeostasis to a cellular state devoid of
pro-survival signals, thereby providing
grounds for a remarkable inhibitor
sensitivity.15
We hypothesized that the mechanisms
that lead to inhibitor hypersensitivity (as
well as resistance) attack points of network hypersensitivity and fragility. Since
preferential Akt activation is a hallmark
of the hyper-sensitive mutants and the
eﬃcacy of the inhibitors, we determine
through a global sensitivity analysis14,15
the combinations of model parameter
perturbations that drive enhanced production of Akt-(p) and ERK-(p).
Table 1b reports the components (rate
constants and initial concentrations) of
the top 3 principal eigenvectors derived
y The phenomenological model can be summarized by: Akt # Akt-(p) - S, with equilibrium constant K1 = [Akt-(p)]/[Akt] and rate
constant k1; D-ind - D, with rate constant
k2; Akt-(p) + D-ind # Akt-(p)D-ind with
equilibrium constant K2 = [Akt-(p)D-ind]/
[Akt-(p)][D-ind] and can be solved analytically. In this model, the cellular states S and
D denote survival and death and D-ind denotes a death-inducing factor. The three reactions capture the eﬀect of Akt on cell
response: i.e., Akt activating survival pathways
and
simultaneously
inhibiting
death-inducing pathways.
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from the parameter variations in our
network in Fig. 1b. Perturbing the components of these principal eigenvectors
(i.e. the entries in Table 1(b)) produces
maximum changes to the Akt-(p) and
ERK-(p) levels. Interestingly, there is a
striking correlation between the components of Table 1(b) resulting from our
model sensitivity analysis and patterns of
oncogenic mutations and mechanisms of
drug resistance found in clinical studies.
High frequency of mutations of PI3K,
Ras (a GTPase named as an acronym for
rat sarcoma), Gab-1, MEK (mitogen
activated protein kinase kinase), Raf
(a serine/threonine kinase which activates
MEK) have all been observed in several
human cancers.29–33 Moreover, it has
been established in screened breast and
colorectal cancer patients that the GAB-1,
MEK, and Ras mutations are nonrandom and likely arise from selective
evolutionary pressures that give the cancer cells a survival advantage.33 With
reference to the hyper-sensitive ErbB1
mutants found in non-small cell lung
cancer patients, the perturbation of the
phosphotyrosine kinetics of Y1068 and
Y1173 through mutations (L834R and
del L723–P729 ins S) is directly responsible for the diﬀerential signaling leading
to preferential Akt activation, as we have
shown in Table 1a. Other sensitive quantities reported in Table 1b also have
direct relevance to hyper-sensitive signaling and drug resistance in the L834R and
del L723–P729 ins S mutant cell lines.
The inhibitor concentration is the most
obvious and is generally depleted in the
cells via multi-drug resistance mechanisms involving drug eﬄux pumps.34 The
restoration of signaling via reduction of
Ki of the inhibitor and the simultaneous
enhancement of KM associated with ATP
binding has also been reported through a
double mutation of L834R/T766M.35,36
This double mutant increases receptor
phosphorylation (Y1068 and Y1173)
kinetics 100-fold24 while simultaneously
decreasing inhibitor aﬃnity.36 Another
drug resistance mechanism related to
Y1068 kinetics (i.e. by circumventing
Y1068 involvement and restoring downstream signaling through an alternative
branch) has been identiﬁed: in the presence of ErbB3, a branch of signaling
analogous to that through Y1068 becomes available through ErbB1-3 heterodimerization directly resulting in PI3K
This journal is
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recruitment on ErbB3 and subsequent
Akt activation. Indeed phosphorylation
of ErbB3 by the Met receptor kinase,
(Met receptor tyrosine kinase is a highaﬃnity transmembrane receptor for the
hepatocyte growth factor), due to overexpression of the Met receptor leads to drug
resistance to geﬁtinib/erlotinib treatment
(inhibition) of ErbB1.37 A drug resistance mechanism involving the change
in expression of the phosphatase associated with Akt has also been identiﬁed
to restore Akt-(p) levels upon inhibitor
treatment.27,38 Roles for the phosphatase
for ERK and the multimeric complex
[ErbB1ShcGrb2SOSRasGTP] (which
are our remaining predictions from
Table 1b) in enhanced signaling and/or
drug resistance have not yet been
established experimentally.

Conclusion and future
outlook
We have employed a multiscale modeling
platform to study ErbB1-mediated signal
transduction, to help rationalize and integrate the collective results emerging
from structural, biochemical, cell biological, and clinical studies. At the molecular level, our results suggest that the
clinically identiﬁed mutations of ErbB1
kinase induce network fragility in the
stabilizing interactions of the inactive
kinase conformation, thereby providing
a persistent stimulus for kinase activation even in the absence of any growth
factor. At a cellular level, parameter
perturbations driving network hypersensitivity through the enhancement of
phosphorylated ERK and Akt levels
show a striking correlation with observed mutations of speciﬁc proteins in
oncogenic cell lines as well as the observed mechanisms of drug resistance to
ErbB1 inhibition. Therefore, subject to
the well-appreciated limitations of computational modeling, i.e., uncertainty in
network topology and parameters,
neglect of molecular cross-talk, autocrine
loops,39 we suggest that cascading
mechanisms of network hypersensitivity/fragility at multiple scales enable
molecular-level perturbations (clinical
mutations) to induce oncogenic transformations and mechanisms of drug resistance. Moreover, our results describe a
possible mechanism of signal branching
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leading to preferential activation of
down-stream molecules (Akt) in the
ErbB1 activating mutants. This preferential activation of a survival factor
makes the cell-lines harboring the mutant receptors to be conducive to oncogenic addiction, i.e. reliance on the
L834R or del L723–P729 ins S ErbB1mediated generation Akt-(p) for survival
signals. The survival pathway addiction
also results in a remarkable sensitivity to
ErbB1 kinase inhibition.
A more complete model description,
which we are currently pursuing, will not
only require resolving the diﬀerential
characteristics of all of the tyrosine phosphorylation sites in ErbB1 (Y992,
Y1086, Y1114, Y1148 Gab1:Y627,
Shc:Y317,
phosphoinositide-speciﬁc
phospholipase Cg or PLCg-1:Y771) and
their associated substrate recognition
properties in ErbB1 (i.e., exploring the
interactions of Gab1, Shc, and PLCg-1
binding to phosphotyrosines of ErbB1
(see recent work by Kholodenko
et al.,40), but also the extension to other
Erb family members in the context of
homo- and hetero-dimers.41 These extensions are especially crucial because transactivation of ErbB1 occurring through
ligand-induced receptor heterodimerization42 combined with a potential for
diﬀerential signaling adds a palette of
ﬁner control elements in the ErbB-family
signaling network. This view is further
bolstered by the over-expression of
ErbB3 in drug resistance to ErbB1 targeting (as discussed above) and mutations
and over-expression of ErbB2 in diﬀerent cancers.43 Moreover, the internalization mechanism of receptors via
endocytosis, which we have not considered in our model, features in crucial
regulatory roles:44 attenuation of endocytosis45 leading to impaired deactivation of receptor tyrosine kinases is
linked to hyper-proliferative conditions
such as cancer.46–48 Hendriks et al.48
proposed a mechanism of diﬀerential
signaling and preferential activation of
Akt in ErbB1 mutants based on reduced
internalization rates of ErbB1 mutants
(relative to wildtype). Hence we are developing the orchestrated vesicular assembly
(OVA) model, which will serve as a
multiscale, spatially-resolved model for
describing the ErbB1 receptor internalization through endocytotic vesicle
formation. In the OVA model, the
Mol. BioSyst., 2008, 4, 1151–1159 | 1157
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membrane dynamics are represented by
the time-dependent Ginzburg Landau
formalism, and the dynamics of accessory proteins, including the curvatureinducing protein, epsin, are represented
by the kinetic Monte Carlo formalism.
The integration of the two formalisms
(Fig. 1c) is described in ref. 12 and 17.
Protein–protein interactions and protein–
membrane interactions are considered
using coarse-grained potentials, and a
phenomenological model for the eﬀect
of a clathrin coat is employed and the
treatment of the membrane to allow for
extreme deformations is through the surface evolution approach (see inset in
Fig. 1c) (unpublished results). Through
the OVA model simulations, we propose
to address the biological question of how
the cell stages the endocytosis nucleation
event to speciﬁc sites on the membrane,
i.e. to the site of a phosphorylated receptor protein; in particular, how does
the network of accessory proteins identify the site of nucleation and synchronize
with the receptor phosphorylation. A
comprehensive multiscale model for
ErbB activation and internalization can
then be achieved by integrating the OVA
model, Fig. 1c, with the network model
we have outlined in Fig. 1b.
At the molecular level, considering
that there is an excellent correlation
between the stabilizing network of interactions and the clinically identiﬁed activating mutations in ErbB1, our structural
studies on kinase activation are well
poised to forecast the mutation landscape associated with other ErbB members. Indeed based on our simulations of
ErbB2 and ErbB4, we have identiﬁed
similar networks of stabilizing residues
and are already able to predict activating
mutations (data not presented) in these
receptors that have not yet been reported
clinically, which together with the extensions proposed above can be valuable for
evaluating the likely eﬀect of mutations
on ErbB2 inhibition eﬃcacies in cancer,
and ErbB4 inhibition in cardiac development and schizophrenia.11
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